Chemical Synthesis Method of Plesiomonas Shigelloides Serotype O51 O-antigen Oligosaccharide
US-2019233459-A1 · Aug 1, 2019 · US
Compositions, methods and uses for expression of enterobacterium-associated peptides
US9028809B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9028809-B2 |
| Application number | US-201013511652-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 24, 2010 |
| Priority date | Nov 24, 2009 |
| Publication date | May 12, 2015 |
| Grant date | May 12, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing enterobacterial-associated peptides. In some embodiments, enterobacterial-associated peptides include, but are not limited to plague-associated peptides. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to, attenuated or modified vaccinia virus vectors expressing enterobacterial-associated peptides. In other embodiments, vaccine compositions are reported of use in a subject.
First claim
Opening claim text (preview).
What is claimed is: 1. An immunogenic composition comprising: one or more constructs of live attenuated, modified vaccinia Ankara (MVA) viruses encoding: at least one V 307 peptide which is the C-terminally truncated low-calcium response V (LcrV) protein antigen of Yersinia pestis lacking its C-terminal amino acids 308 to 326 and a mammalian secretory signal sequence and a viral translational control sequence, wherein the mammalian secretory signal sequence is tissue plasmi…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9028809B2 cover?
- Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing enterobacterial-associated peptides. In some embodiments, enterobacterial-associated peptides include, but are not limited to plague-associated peptides. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to,…
- Who is the assignee on this patent?
- Stinchcomb Dan T, Osorio Jorge E, Powell Timothy D, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification A61K39/025. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 12 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).